Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis

Cardiovascular Diabetology
Yechen HanZhujun Shen

Abstract

Metformin is the most widely prescribed drug to lower glucose and has a definitive effect on the cardiovascular system. The goal of this systematic review and meta-analysis is to assess the effects of metformin on mortality and cardiac function among patients with coronary artery disease (CAD). Relevant studies reported before October 2018 was retrieved from databases including PubMed, EMBASE, Cochrane Library and Web of Science. Hazard ratio (HR) was calculated to evaluate the all-cause mortality, cardiovascular mortality and incidence of cardiovascular events (CV events), to figure out the level of left ventricular ejection fraction (LVEF), creatine kinase MB (CK-MB), type B natriuretic peptide (BNP) and to compare the average level of low density lipoprotein (LDL). In this meta-analysis were included 40 studies comprising 1,066,408 patients. The cardiovascular mortality, all-cause mortality and incidence of CV events were lowered to adjusted HR (aHR) = 0.81, aHR = 0.67 and aHR = 0. 83 respectively after the patients with CAD were given metformin. Subgroup analysis showed that metformin reduced all-cause mortality in myocardial infarction (MI) (aHR = 0.79) and heart failure (HF) patients (aHR = 0.84), the incidence of CV even...Continue Reading

References

Oct 18, 2002·European Journal of Internal Medicine·Rita RachmaniMordchai Ravid
Mar 1, 2005·Diabetes Care·Raj PadwalFinlay A McAlister
Mar 25, 2005·Diabetic Medicine : a Journal of the British Diabetic Association·J A JohnsonS R Majumdar
Jul 23, 2009·BMJ : British Medical Journal·David MoherUNKNOWN PRISMA Group
Mar 9, 2010·Journal of Cardiac Failure·Digish D ShahTamara B Horwich
Nov 26, 2010·Archives of Internal Medicine·Ronan RousselUNKNOWN Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators
Jun 29, 2012·European Journal of Heart Failure·Aaron K F WongChim C Lang
Mar 14, 2014·The Lancet. Diabetes & Endocrinology·David PreissNaveed Sattar
Apr 2, 2014·JAMA : the Journal of the American Medical Association·Chris P H LexisUNKNOWN GIPS-III Investigators
Jun 13, 2015·Cardiovascular Drugs and Therapy·Amjad AbualsuodJawahar L Mehta
Apr 12, 2016·Clinical Therapeutics·Christopher B ChenJeffrey A Johnson
Jun 25, 2016·Journal of Cardiovascular Medicine·Lorenzo FácilaJulio Núñez
Feb 14, 2017·Journal of Diabetes and Its Complications·Chen-Pin WangSara E Espinoza
Apr 21, 2017·Journal of the American Heart Association·Christianne L RoumieMarie R Griffin

❮ Previous
Next ❯

Citations

Feb 6, 2020·Diabetes, Obesity & Metabolism·John R PetrieIan W Campbell
Jan 4, 2020·GeroScience·Kiran ChaudhariShao-Hua Yang
Aug 21, 2020·BMC Medicine·Hubert KolbStephan Martin
Jun 4, 2020·Diabetology & Metabolic Syndrome·Marcello Casaccia BertoluciCristiane Bauermann Leitão
Jul 23, 2020·Dose-response : a Publication of International Hormesis Society·Mingming ZhangXuesong Xu
Sep 18, 2020·Journal of Cardiac Surgery·Marco Shiu Tsun LeungAmer Harky
Oct 13, 2020·Frontiers in Physiology·Mario SchubertKaomei Guan
Nov 26, 2020·Cardiovascular Diabetology·Teerapat NantsupawatNipon Chattipakorn
Nov 25, 2020·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Viveca RitsingerAnna Norhammar
Dec 3, 2020·Pharmaceuticals·Ehtasham AhmadMelanie J Davies
Jan 4, 2021·Journal of Molecular Histology·Fatma MostafaHanaa M Mohamed
Jan 4, 2021·Atencion primaria·Domingo Orozco-BeltránJorge Navarro Pérez
Jul 2, 2020·Seminars in Cancer Biology·Wei-Kai WuAlexander N Orekhov
Nov 6, 2020·Diabetes & Metabolism·Anthony P Sunjaya, Angela F Sunjaya
Nov 22, 2020·Current Problems in Cardiology·Lauren D BreiteBrandon E Cave
Nov 5, 2020·Mechanisms of Ageing and Development·Samir Morsli, Ilaria Bellantuono
Nov 20, 2020·BMJ Open Respiratory Research·Amr AlderawiPaul Kirkham
Nov 17, 2020·Frontiers in Cellular and Infection Microbiology·Qi-You DingXiao-Lin Tong
Jan 26, 2021·Therapeutic Advances in Endocrinology and Metabolism·Chelsea BakerNeda Rasouli
Dec 15, 2020·Frontiers in Endocrinology·Jing OuyangJean-Pierre Routy
Feb 9, 2021·Frontiers in Physiology·Amit K RaiVenkata Naga Srikanth Garikipati
Dec 15, 2020·Scientific Reports·Angelica GiulianiJacopo Sabbatinelli
Feb 11, 2021·Pharmaceuticals·Józef Drzewoski, Markolf Hanefeld
Feb 21, 2021·Diabetes Care·Andrea GiaccariStefano Del Prato
Nov 13, 2020·Diabetes Research and Clinical Practice·Awadhesh Kumar Singh, Ritu Singh
Feb 27, 2021·Cardiovascular Endocrinology & Metabolism·Ricardo J RojasSalomón Huancahuire-Vega
Feb 23, 2021·Oncotarget·Mikhail V Blagosklonny
Mar 24, 2021·Future Cardiology·Ez Alddin Rajjoub Al-MahdiJose L Zamorano
Jul 11, 2020·European Journal of Pharmacology·Moumita NathYashmin Choudhury
Apr 4, 2021·International Journal of Molecular Sciences·Mojca LunderMišo Šabovič
Apr 8, 2021·Annals of Vascular Surgery·Agnieszka TurowiczMariusz Chabowski
Apr 15, 2021·Deutsche medizinische Wochenschrift·Thomas Münzer
Apr 18, 2021·Metabolism: Clinical and Experimental·Emir MuzurovićChristos Mantzoros
Mar 11, 2021·American Journal of Physiology. Cell Physiology·Leena P Bharath, Barbara S Nikolajczyk
Jul 27, 2021·Environmental Toxicology and Pharmacology·Jessica PhillipsTracie R Baker

❮ Previous
Next ❯

Software Mentioned

Review Manager

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.